Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30–46%) at 2 years and 25% (17–32%) at 5 ye...

Descripción completa

Detalles Bibliográficos
Autores principales: Hayden, Patrick J., Eikema, Dirk-Jan, de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus, Einsele, Hermann, Minnema, Monique, Dominietto, Alida, Potter, Michael, Passweg, Jacob, Bermúdez, Arancha, Nguyen-quoc, Stephanie, Platzbecker, Uwe, Tischer, Johanna, Ciceri, Fabio, Veelken, Joan Hendrik, Ljungman, Per, Schaap, Nicolaas, Forcade, Edouard, Carella, Angelo Michele, Gandemer, Virginie, Arcese, William, Bloor, Adrian, Olivieri, Attilio, Vincent, Laure, Beksac, Meral, Schönland, Stefan, Yakoub-Agha, Ibrahim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486670/
https://www.ncbi.nlm.nih.gov/pubmed/33976382
http://dx.doi.org/10.1038/s41409-021-01286-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486670/
https://www.ncbi.nlm.nih.gov/pubmed/33976382
http://dx.doi.org/10.1038/s41409-021-01286-x

Ejemplares similares